MTCR
Metacrine, Inc.
A clinical-stage biopharmaceutical company developing oral medicines for liver and metabolic diseases, Metacrine works on treatments for conditions like non-alcoholic steatohepatitis (NASH) and diabetes. It was founded in 2015 by scientists from the Salk Institute, and its name blends "meta" (metabolism) with "crine" (secretion), reflecting its focus on metabolic pathways. The company was based in San Diego, California.
CUSIP: 59101E103HealthcareUS1 holder
Total Value
$965.0K
Total Shares
281.5K
Net Share Change
-764.7K
Activity
1 selling
Investor
Value
Shares
Weight
Change
